Understanding how TIRR affects the function of the p53 protein in cancer
Elucidating the molecular mechanism and physiological relevance of TIRR mediated inhibition of p53
['FUNDING_R01'] · DANA-FARBER CANCER INST · NIH-10845530
This study is looking at how a protein called TIRR helps another important protein, p53, do its job in protecting our cells from cancer by responding to DNA damage, and understanding this could lead to new treatments for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10845530 on ClinicalTrials.gov |
What this research studies
This research investigates the role of TIRR, a protein that interacts with 53BP1, in regulating the function of p53, a crucial protein involved in preventing cancer. The study aims to clarify how TIRR influences the ability of p53 to respond to DNA damage and maintain genome stability. By examining the molecular mechanisms at play, the research seeks to uncover new insights into how disruptions in these interactions may contribute to cancer development. Patients may benefit from a better understanding of these processes, which could lead to novel therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers where p53 function is known to be compromised.
Not a fit: Patients with cancers unrelated to p53 dysfunction may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the effectiveness of p53 in preventing cancer.
How similar studies have performed: Other research has shown promising results in understanding the role of p53 and its regulators in cancer biology, indicating that this approach has potential for success.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHOWDHURY, DIPANJAN — DANA-FARBER CANCER INST
- Study coordinator: CHOWDHURY, DIPANJAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Biology, Cancer Cause, Cancer Etiology, Cancers